WHO ICTRP trial
Celecoxib in the treatment of obsessive-compulsive disorder
IRCT201312181556N56 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT201312181556N56 |
|---|---|
| Public title | Celecoxib in the treatment of obsessive-compulsive disorder |
| Scientific title | Celecoxib as adjuant therapy in the treatment of OCD: a double blind randomized trial |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder;Obsessive-compulsive disorder |
| Interventions | Intervention 1: Tablet fluvoxamine (100 mg/day) combined with 400 mg/day of Tablets celecoxib as intervention group for 10 weeks. Intervention 2: Tablet fluvoxamine (100 mg/day) combined with placebo as control group for 10 weeks.;Treatment… |
| Registration date | Dec 23, 2013 |
| Target size | 50 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: